Chartsbank is a comprehensive database containing information on more than 3000 new drugs in development, inclusive of pre-clinical research up to phase IV development

Subscribers view details.


 
Please Select Filter Criteria for the drug pipeline
Drug Pipeline by drug name:
Drug Pipeline by Company:
Drug Pipeline by Disease:

Subscribe

Drug Pipeline by Generic :
Drug Pipeline by Current Status:
Drug Pipeline by ICN:

...11121314151617181920...
CompanyDrug NameStatusIndication Group
Telik Telcyta and Cisplatin in Phase IIAntineoplastic & immunomodulating agents
Telik Telcyta and carboplatin and paclitaxel in Phase IIIAntineoplastic & immunomodulating agents
Telik Telcyta accomplished Phase IIIAntineoplastic & immunomodulating agents
Telik Telcyta accomplished Phase IIIAntineoplastic & immunomodulating agents
Biovail Teczem N/ACardiovascular system
Wex Tectin in Phase IIINervous system
Allergan TAZORAC Submitted for approval in USADermatologicals
Sanofi-aventis Taxotere accomplished Phase IIAntineoplastic & immunomodulating agents
Sanofi-aventis Taxotere Approved in USAAntineoplastic & immunomodulating agents
Sanofi-aventis Taxotere Approved in USA and EUAntineoplastic & immunomodulating agents
Sanofi-aventis Taxotere Approved in EU and USAAntineoplastic & immunomodulating agents
BioNumerik Tavocept in Phase IIIAntineoplastic & immunomodulating agents
BioNumerik Tavocept in Phase IAntineoplastic & immunomodulating agents
Peregrine Tarvacin accomplished Phase IAntineoplastic & immunomodulating agents
Xenova Group Tariquidar accomplished Phase IAntineoplastic & immunomodulating agents
Genentech Tarceva in Phase IIAntineoplastic & immunomodulating agents
Roche Tarceva in Phase IIAntineoplastic & immunomodulating agents
OSI Tarceva Approved in USA and EUAntineoplastic & immunomodulating agents
Genentech Tarceva Approved in USAAntineoplastic & immunomodulating agents
Genentech Tarceva Approved in EU and USAAntineoplastic & immunomodulating agents
...11121314151617181920...




Drug Pipeline Copyright © 2005- 2017 All Rights Reserved.